Showing posts with label Works. Show all posts
Showing posts with label Works. Show all posts

Tuesday, 2 July 2013

Hawaii: O'Keeffe, Adams works together at Honolulu museum (LA Times)

Sorry, I could not read the content fromt this page.Sorry, I could not read the content fromt this page.

View the original article here

Wednesday, 19 June 2013

Less Invasive Autopsy Works Nearly as Well (CME/CE)

Register Today

Earn Free CME Credits by reading the latest medical news
in your specialty.

Sign Up
By Todd Neale, Senior Staff Writer, MedPage Today Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse PlannerA minimally invasive approach using postmortem MRI may represent a viable alternative to a conventional autopsy in fetuses, children, and teens.Note that the concordance between whole-body MRI and postmortem exam was greatest in fetuses and declined with increasing age among the children.

A minimally invasive approach using postmortem MRI may represent a viable alternative to a conventional autopsy in fetuses, children, and teens, researchers found.

In fetuses and individuals 16 and younger, a minimally invasive autopsy that included MRI identified the same cause of death or major pathological abnormality that a conventional autopsy did in 89.3% of cases, according to Sudhin Thayyil, PhD, of University College London, and colleagues.

The concordance was greatest in fetuses and declined with increasing age among the children, the researchers reported online in The Lancet.

"Thus, minimally invasive autopsy could be a suitable alternative to conventional autopsy for detection of cause of death or major pathological lesions in selected cases for which an invasive postmortem examination is unacceptable," they wrote.

It is important to closely involve parents in the process of establishing a minimally invasive autopsy program, "and contrary to popular belief, bereaved parents often view this involvement positively," they added. "Future studies should examine the clinical, psychological, epidemiological, and economic effect of minimally invasive autopsy."

In recent years, rates of autopsy have fallen in developed countries for a variety of reasons, including objection by the families of the deceased.

Some studies have evaluated postmortem MRI as a more acceptable alternative to conventional autopsy, but there is limited evidence regarding its accuracy.

In the current prospective study performed at two London centers, Thayyil and colleagues compared autopsy performed using postmortem, whole-body MRI with or without other minimally invasive tools with that performed by conventional means for 400 cases -- 69% were fetuses and 31% were children 16 or younger.

The average time from death or delivery and the postmortem MRI was 4.5 days. The images were interpreted by pediatric radiologists -- one each for the nervous, cardiovascular, pulmonary and abdominal, and musculoskeletal body systems for each case.

Compared with conventional autopsy, the accuracy of the minimally invasive approach for identifying the cause of death or a major pathological change varied according to the age of the cases: 94.6% for fetuses at 24 weeks of gestation or less95.7% for fetuses at more than 24 weeks of gestation81% for newborns 1 month or younger84.9% for infants age 1 month to 1 year53.6% for children older than 1 year

"The lower concordance in children than fetuses was mainly due to undetected pneumonia and myocarditis," the researchers noted.

"This finding is expected, and is almost certainly related to the changing pattern of underlying pathological changes associated with autopsy across this age range, from mostly structural anomalies in fetuses to mostly infective causes in infancy and older children," they wrote.

A radiologist and a pathologist who did not know the results of the autopsy used a set of predefined criteria to determine whether the minimally invasive approach would have been sufficient for each case; they determined that a full autopsy might not have been necessary in 41% of cases. The minimally invasive and conventional approaches yielded similar findings in 99.4% of those cases.

The authors acknowledged some limitations of the analysis, including the uncertain applicability to less specialized settings, the inclusion of only those cases for which consent for conventional autopsy was obtained, and the lack of information on the economic aspects of postmortem MRI.

"Although minimally invasive autopsy can be less expensive than conventional autopsy, the overall cost of postmortem services might rise because parents who decide against autopsy might want a minimally invasive autopsy, which paradoxically increases the workload for both pathologists and radiologists," Thayyil and colleagues wrote.

Despite those limitations, however, the researchers "have presented a starting point for development of a robust system for postmortem diagnosis using various modalities (i.e., pathology, radiology, laboratory testing) and a system of interdisciplinary consultation and collaborative diagnosis, mimicking systems for optimum diagnostic assessment of living patients," according to Corinne Fligner, MD, and Manjiri Dighe, MD, both of the University of Washington in Seattle.

"Some deaths could be assessed with minimally invasive autopsy," they wrote in an accompanying editorial, "but some investigations will mandate use of conventional autopsy."

The paper is an independent report commissioned and funded by the Policy Research Program in the U.K. Department of Health. The study was also supported by grants from the British Heart Foundation, Wellbeing of Women and Stillbirth and Neonatal Death charities, and Foundation for the Study of Infant Deaths.

Thayyil has received a Clinician Scientist Award from the National Institute for Health Research. His co-authors reported support from the National Institute for Health Research, the Foundation Leducq, the Higher Education Funding Council for England, and the Great Ormond Street Hospital for Children NHS Foundation Trust Charity.

The study authors and the editorialists reported that they had no conflicts of interest.

Todd Neale

Senior Staff Writer

Todd Neale, MedPage Today Staff Writer, got his start in journalism at Audubon Magazine and made a stop in directory publishing before landing at MedPage Today. He received a B.S. in biology from the University of Massachusetts Amherst and an M.A. in journalism from the Science, Health, and Environmental Reporting program at New York University.

Tuesday, 18 June 2013

Biomarker for Asbestos-Linked Cancer Works (CME/CE)

Register Today

Earn Free CME Credits by reading the latest medical news
in your specialty.

Sign Up
By Michael Smith, North American Correspondent, MedPage Today Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse PlannerThis study suggests that plasma fibulin-3 levels can distinguish healthy persons with exposure to asbestos from patients with mesothelioma.The study also suggests that in conjunction with effusion fibulin-3 levels, plasma fibulin-3 levels can differentiate mesothelioma effusions from other malignant and benign effusions.

Glycoprotein fibulin-3 can be used to identify patients with pleural mesothelioma and may be a useful biomarker for the asbestos-related illness, researchers reported.

Plasma levels of the protein were higher in people with the disease than they were in people exposed to asbestos but who did not have mesothelioma, according to Harvey Pass, MD, of New York University Langone Medical Center in New York City, and colleagues.

And levels in effusions from mesothelioma patients were higher than they were in patients with effusions from other causes, Pass and colleagues reported in the Oct. 11 issue of the New England Journal of Medicine.

On the other hand, the researchers cautioned, it's too early to say that the protein can be used for early detection because of a lack of prospective longitudinal studies.

Despite advances in therapy, median survival for pleural mesothelioma remains about a year from diagnosis, the researchers noted.

Earlier detection might help, but "is limited by the long latency period, an inability of imaging to detect the disease at an early stage even when it is used as a screening strategy, and the lack of sensitive and specific blood-based markers."

The latter gap, they hypothesized, might be filled by fibulin-3 if it could be shown to be a "robust biomarker."

To test the idea, they measured fibulin-3 levels in stored plasma samples from 92 patients with mesothelioma, 136 people exposed to asbestos but who did not have the disease, 93 patients with effusions not caused by mesothelioma, and 43 healthy controls.

They also measured levels in stored effusions from 74 patients with mesothelioma, 39 with benign effusions, and 54 with malignant effusions not caused by mesothelioma. Some participants had both types of samples.

The stored samples were collected in Detroit from 1998 through 2005 and in New York from 2005 through 2011, Pass and colleagues reported.

The researchers also conducted two validation analyses – one each using serum and plasma from mesothelioma patients and cancer-free people with asbestos exposure.

Plasma fibulin-3 levels did not vary according to age, sex, duration of asbestos exposure, or degree of radiographic changes.

On the other hand, they were significantly higher in patients with pleural mesothelioma than in asbestos-exposed people without the disease. In the Detroit cohort, mesothelioma patients averaged 105 nanograms per ml of plasma, compared with 13.9 among the asbestos-exposed controls (P<0.001) and in the New York cohort, the respective averages were 112.9 and 24.3 nanograms per ml (P<0.001).

The same was true for fibulin-3 levels in effusions.

In the Detroit cohort, effusion levels averaged 694.4 nanograms per ml higher in patients with pleural mesothelioma and 211.5 in patients with effusion from other causes. In the New York cohort, the respective averages were 636.4 and 150.6 nanograms per milliliter. Both differences were, again, significant at P<0.001.

In the validation study using serum, fibulin-3 levels were unable to discriminate between patients with mesothelioma and those exposed to asbestos but cancer-free, Pass and colleagues reported.

One possible explanation is that the samples, which were collected from 1985 through 1996 during the Carotene and Retinol Efficacy Trial, might have degraded over time, they suggested.

In the other validation study, a set of plasma samples from the University of Toronto showed lower levels in both patients and asbestos-exposed controls than either of the American cohorts – 66.4 and 13.9 nanograms per milliliter, respectively.

But, Pass and colleagues reported, the difference remained significant at P<0.001.

In an overall comparison of patients with and without mesothelioma, the researchers reported, the receiver-operating-characteristic curve for plasma fibulin-3 levels had a sensitivity of 96.7% and a specificity of 95.5% at a cutoff value of 52.8 nanograms per milliliter.

While more research is needed, they concluded, plasma fibulin-3 levels can help tell people with mesothelioma from those who remain healthy after exposure to asbestos.

Together with levels in effusions, plasma fibulin-3 can also differentiate mesothelioma effusions from other malignant and benign effusions, they argued.

The study had support from the Princess Margaret Hospital Foundation, the Princess Margaret Hospital Mesothelioma Research Program (funded by the Masters Insulators Association of Ontario, International Association of Heat and Frost Insulators and Asbestos Workers, Local 793, and other unions, and the Imperial Oil Charitable Foundation), the M. Qasim Choksi Chair in Lung Cancer Translational Research, the Alan B. Brown Chair in Molecular Genetics, the Ontario Ministry of Health and Long-Term Care, Belluck and Fox, the Simmons Foundation, Levi Phillips and Konigsberg, the Stephen E. Banner Fund for Lung Cancer Research, the Rosenwald Family, the Anderson Family, and the NIH.

Pass reported fnancial links with Champions Oncology, Rosetta Genomics, Pinpoint Genomcs, and SomaLogic.

Michael Smith

North American Correspondent

North American Correspondent for MedPage Today, is a three-time winner of the Science and Society Journalism Award of the Canadian Science Writers' Association. After working for newspapers in several parts of Canada, he was the science writer for the Toronto Star before becoming a freelancer in 1994. His byline has appeared in New Scientist, Science, the Globe and Mail, United Press International, Toronto Life, Canadian Business, the Toronto Star, Marketing Computers, and many others. He is based in Toronto, and when not transforming dense science into compelling prose he can usually be found sailing.